Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
estradiol + norethisterone acetate
- Development stage
- Phase 4
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Transdermal
01
Overview
Estracomb TTS is a sequential transdermal hormone replacement therapy (HRT) patch system developed by Ciba-Geigy (now Novartis). It is indicated for the relief of menopausal and postmenopausal symptoms (such as hot flashes, sleep disturbances, and urogenital atrophy) and the prevention of postmenopausal osteoporosis in women with an intact uterus. The sequential regimen consists of two types of patches: Estraderm TTS (delivering estradiol only) used for the first 14 days of a 28-day cycle, followed by Estragest TTS (delivering a combination of estradiol and norethisterone acetate) used for the remaining 14 days. Estradiol acts as an agonist of estrogen receptors to alleviate estrogen deficiency symptoms, while norethisterone acetate, a synthetic progestin, acts as a progesterone receptor agonist to prevent estrogen-induced endometrial hyperplasia.
- Brand names
- EstracombEstracomb TTSEstracombi
- Other names
- estradiol + norethindrone acetateestradiol + norethisterone acetate
02
Targets
ESR2 (ERβ)ESR1 (ERα)PR (Progesterone receptor)
Beyond the preview
Go deeper on estradiol + norethisterone acetate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on estradiol + norethisterone acetate.